[1] ALSAAB H O,SAU S,ALZHRANI R,et al.PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy:mechanism,combinations,and clinical outcome[J].Front Pharmacol,2017,8:561.
[2] LIU S V,RECK M,MANSFIELD A S,et al.Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab,carboplatin,and etoposide(IMpower133)[J].J Clin Oncol,2021,39(6):619-630.
[3] GADGEEL S M,PENNELL N A,FIDLER M J,et al.Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer(SCLC)[J].J Thorac Oncol,2018,13(9):1393-1399.
[4] ARRIOLA E,GONZáLEZ-CAO M,DOMINE M,et al.Addition of immune checkpoint inhibitors to chemotherapy vs chemotherapy alone as first-line treatment in extensive-stage small-cell lung carcinoma:a systematic review and meta-analysis[J].Oncol Ther,2022,10(1):167-184.
[5] SUN J M,SHEN L,SHAH M A,et al.Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer(KEYNOTE-590):a randomised,placebo-controlled,phase 3 study[J].Lancet,2021,398(10302):759-771.
[6] KELLY R J,AJANI J A,KUZDZAL J,et al.Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J].N Engl J Med,2021,384(13):1191-1203.
[7] HUANG J,XU J,CHEN Y,et al.Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma(ESCORT):a multicentre,randomised,open-label,phase 3 study[J].Lancet Oncol,2020,21(6):832-842.
[8] RYOO B Y,MERLE P,KULKARNI A S,et al.Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma:KEYNOTE-240[J].Cancer,2021,127(6):865-874.
[9] KUDO M,MOTOMURA K,WADA Y,et al.Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma:results from the phase 1b VEGF liver 100 trial[J].Liver Cancer,2021,10(3):249-259.
[10] JANJIGIAN Y Y,KAWAZOE A,YAÑEZ P,et al.The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J].Nature,2021,600(7890):727-730.
[11] SUN Y,LI W,LI A J,et al.Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative,HER2-positive breast cancer patients[J].Cancer Manag Res,2019,11:3153-3162.
[12] SCHETTINI F,PRAT A.Dissecting the biological heterogeneity of HER2-positive breast cancer[J].Breast,2021,59:339-350.
[13] POZNANSKI S M,RITCHIE T M,FAN I Y,et al.Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy[J].J Immunother Cancer,2021,9(1):e001933.
[14] ZHANG C,RÖDER J,SCHERER A,et al.Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity[J].J Immunother Cancer,2021,9(10):e002980.
[15] TAO B,DU R,ZHANG X,et al.Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy[J].J Control Release,2023,363:692-706.
[16] XIA W,CHEN J,HOU W,et al.Engineering a HER2-CAR-NK cell secreting soluble programmed cell death protein with superior antitumor efficacy[J].Int J Mol Sci,2023,24(7):6843.
[17] KRASNIQI E,BARCHIESI G,PIZZUTI L,et al.Immunotherapy in HER2-positive breast cancer:state of the art and future perspectives[J].J Hematol Oncol,2019,12(1):111.
[18] ÖZVEREL C S,UYANIKGIL Y,KARABOZ I·,et al.Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant:effect against HER2 positive breast cancer in mice[J].Immunopharmacol Immunotoxicol,2020,42(4):346-357.
[19] KODUMUDI K N,RAMAMOORTHI G,SNYDER C,et al.Sequential anti-PD1 therapy following dendritic cell vaccination improves survival in a HER2 mammary carcinoma model and identifies a critical role for CD4 T cells in mediating the response[J].Front Immunol,2019,10:1939.
[20] ZHENG G,GUO Z,LI W,et al.Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab[J].Signal Transduct Target Ther,2021,6(1):236.
[21] LI R,SANT S,BROWN E,et al.Tucatinib promotes immune activation and synergizes with programmed cell death-1 and programmed cell death-ligand 1 inhibition in HER2-positive breast cancer[J].J Natl Cancer Inst,2023,115(7):805-814.
[22] HUANG L,WANG R,XIE K,et al.A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation[J].Breast Cancer Res Treat,2022,191(1):51-61.
[23] IWATA T N,ISHII C,ISHIDA S,et al.A HER2-targeting antibody-drug conjugate,trastuzumab deruxtecan(DS-8201a),enhances antitumor immunity in a mouse model[J].Mol Cancer Ther,2018,17(7):1494-1503.
[24] DIÉRAS V,MILES D,VERMA S,et al.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer(EMILIA):a descriptive analysis of final overall survival results from a randomised,open-label,phase 3 trial[J].Lancet Oncol,2017,18(6):732-742.
[25] MVLLER P,KREUZALER M,KHAN T,et al.Trastuzumab emtansine(T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade[J].Sci Transl Med,2015,7(315):315ra188.
[26] MITTAL D,VIJAYAN D,NEIJSSEN J,et al.Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy[J].Oncoimmunology,2019,8(11):e1648171.
[27] CHENG Q,ZHANG X N,LI J,et al.Synthesis of bispecific antibody conjugates using functionalized poly-ADP-ribose polymers[J].Biochemistry,2023,62(6):1138-1144.
[28] LEAL A S,MOERLAND J A,ZHANG D,et al.The RXR agonist MSU42011 is effective for the treatment of preclinical HER2+ breast cancer and Kras-driven lung cancer[J].Cancers(Basel),2021,13(19):5004.
[29] D'AMICO L,MENZEL U,PRUMMER M,et al.A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer[J].J Immunother Cancer,2019,7(1):16.
[30] LOI S,GIOBBIE-HURDER A,GOMBOS A,et al.Pembrolizumab plus trastuzumab in trastuzumab-resistant,advanced,HER2-positive breast cancer(PANACEA):a single-arm,multicentre,phase 1b-2 trial[J].Lancet Oncol,2019,20(3):371-382.
[31] 薛玉,顾军.HER2阳性乳腺癌曲妥珠单抗耐药机制及应对策略研究进展[J].东南大学学报(医学版),2019,38(5):923-928.
[32] BORGHAEI H,BESSE B,BARDIA A,et al.Trastuzumab deruxtecan(T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer(NSCLC):a phase Ib,multicenter,study[J].JCO,2020,38(15_suppl):TPS1100-TPS.
[33] LV H,YAN M,SUN T,et al.Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer:final results from the phase 2 ICU trial[J].JCO,2023,41(16_suppl):1042.
[34] HURVITZ S A,GALSKY M D,SHAHIDI J,et al.A phase Ib,multicenter,open-label study of the antibody-drug conjuga te trastuzumab deruxtecan(DS-8201a) combination with nivolumab for ad vanced HER2-expressing breast or urothelial cancer[J].Ann Oncol,2018,29(Supplement 8):viii121.
[35] EMENS L A,ESTEVA F J,BERESFORD M,et al.305O - overall survival(OS) in KATE2,a phase Ⅱ study of programmed death ligand 1(PD-L1) inhibitor atezolizumab(atezo)+trastuzumab emtansine(T-DM1) vs placebo(pbo)+T-DM1 in previously treated HER2+ advanced breast cancer(BC)[J].Ann Oncol,2019,30(Supplement 5):v104-v142.
[36] SU Q,ZHANG X C,WANG D Y,et al.The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors:a systematic review and meta-analysis[J].Int Immunopharmacol,2018,59:328-338. |
